Risk Assessment in Pulmonary Arterial Hypertension

Article Type
Changed
Wed, 11/09/2022 - 15:50
Display Headline
Risk Assessment in Pulmonary Arterial Hypertension
References
  1. Sahay S, Balasubramanian V, Memon H, et al. Utilization of risk assessment tools in management of PAH: a PAH provider survey. Pulm Circ. 2022;12(2):e12057. doi:10.1002/pul2.12057
  2. Sahay S, Tonelli AR, Selej M, Watson Z, Benza RL. Risk assessment in patients with functional class II pulmonary arterial hypertension: comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score. PLoS One. 2020;15(11):e0241504. doi:10.1371/journal.pone.0241504
  3. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017
  5. Wilson M, Keeley J, Kingman M, Wang J, Rogers F. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ. 2020;10(3):2045894020950186. doi:10.1177/2045894020950186
Publications
Topics
References
  1. Sahay S, Balasubramanian V, Memon H, et al. Utilization of risk assessment tools in management of PAH: a PAH provider survey. Pulm Circ. 2022;12(2):e12057. doi:10.1002/pul2.12057
  2. Sahay S, Tonelli AR, Selej M, Watson Z, Benza RL. Risk assessment in patients with functional class II pulmonary arterial hypertension: comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score. PLoS One. 2020;15(11):e0241504. doi:10.1371/journal.pone.0241504
  3. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017
  5. Wilson M, Keeley J, Kingman M, Wang J, Rogers F. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ. 2020;10(3):2045894020950186. doi:10.1177/2045894020950186
References
  1. Sahay S, Balasubramanian V, Memon H, et al. Utilization of risk assessment tools in management of PAH: a PAH provider survey. Pulm Circ. 2022;12(2):e12057. doi:10.1002/pul2.12057
  2. Sahay S, Tonelli AR, Selej M, Watson Z, Benza RL. Risk assessment in patients with functional class II pulmonary arterial hypertension: comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score. PLoS One. 2020;15(11):e0241504. doi:10.1371/journal.pone.0241504
  3. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018
  4. Boucly A, Weatherald J, Savale L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017;50(2):1700889. doi:10.1183/13993003.00889-2017
  5. Wilson M, Keeley J, Kingman M, Wang J, Rogers F. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ. 2020;10(3):2045894020950186. doi:10.1177/2045894020950186
Publications
Publications
Topics
Article Type
Display Headline
Risk Assessment in Pulmonary Arterial Hypertension
Display Headline
Risk Assessment in Pulmonary Arterial Hypertension
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Mon, 10/24/2022 - 09:00
Un-Gate On Date
Mon, 10/24/2022 - 09:00
Use ProPublica
CFC Schedule Remove Status
Mon, 10/24/2022 - 09:00
Hide sidebar & use full width
Do not render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Article Slideshow Optional Introduction

Properly assessing risk level at the time of diagnosis and follow up is crucial for understanding each patient’s case, identifying modifiable barriers and the most appropriate treatment options, and, ultimately, optimizing survival outcomes for pulmonary arterial hypertension (PAH). Despite the variety of risk assessment tools and electronic medical records at clinicians’ disposal, these resources remain underutilized.1

A survey, designed by CHEST’s Pulmonary Vascular Disease section of the Pulmonary Vascular and Cardiovascular Network, asked members to share insight into their use and perceptions of PAH risk assessment tools in clinical practice. Although the ability of proper risk assessment to greatly improve patient care has been demonstrated in the literature and is recommended by most clinical guidelines, the results of this survey revealed that more than one-third of specialists were not using guideline-recommended risk tools to assess PAH, and only 7% reported that risk assessment tools impacted their treatment decision in new patient care and evaluation.1-4

There is a lack of consensus in patterns of risk tool use among physicians, with 58% reporting that they use more than one tool. In addition to continued clinical research to support the use of available tools and the development of new ones, clinician education programs can help increase the positive impact that risk assessment has on patient survival and other outcomes.1,5

Slide
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
Slide Media